Medical Equipment

Companion Diagnostics Market Developments Influencing Industry Expansion Through 2030

May 12, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Companion Diagnostics Market Become By 2030 Compared To 2026?

The companion diagnostics market has experienced substantial growth in recent years. It is anticipated to increase from $8.69 billion in 2025 to $10.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 21.3%. The market’s historical growth can be attributed to the rise in targeted cancer therapies, the expansion of oncology clinical trials, enhanced collaboration between pharma and diagnostics firms, increasing cancer incidence rates, and regulatory approvals for companion tests.

The companion diagnostics market is projected to experience substantial expansion over the upcoming years, with its valuation expected to reach $22.7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.1%. This anticipated growth during the forecast period stems from several factors, including the escalating need for tailored treatment selection, increased capital allocation towards precision medicine, the proliferation of immuno-oncology pipelines, the rising implementation of AI-powered diagnostic interpretation, and a heightened regulatory focus on the concurrent development of diagnostics and drugs. Furthermore, significant developments anticipated in this period encompass the wider embrace of precision oncology diagnostics, enhanced incorporation of companion diagnostics within drug development processes, a surge in the utilization of NGS-based diagnostic platforms, the broadening scope of biomarker-driven therapeutic approaches, and a stronger emphasis on personalized medicine.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7038&type=smp

What Influential Factors Are Boosting The Companion Diagnostics Market Demand?

The growing number of targeted therapies is projected to boost the companion diagnostics market. Targeted therapy is a pharmacological approach designed to act on specific characteristics of cancer cells, thereby inhibiting disease growth and spread. These medications circulate throughout the body but exhibit a more precise effect than chemotherapy, often leading to fewer adverse effects. Companion diagnostic testing, based on biological markers for targeted cancer therapy, is becoming an essential part of personalized cancer care. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, stated that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Therefore, the expansion in targeted therapies is driving growth in the companion diagnostics market.

What Segment Categories Are Evaluated In The Companion Diagnostics Market Study?

The companion diagnostics market covered in this report is segmented –

1) By Product And Service: Assays, Kits And Reagents, Software And Services

2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry

3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma

4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations

Subsegments:

1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays

2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents

3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

What Trends Are Affecting The Growth Of The Companion Diagnostics Market?

Leading firms within the companion diagnostics market are engaging in cooperative efforts to create advanced treatment solutions, aiming to enhance personalized medical care, improve patient results, and optimize the efficacy of targeted therapies. These collaborations are set to expedite both the development and market introduction of companion diagnostics (CDx) specifically for hematology and oncology treatments. As an illustration, in January 2024, Agilent Technologies, Inc., a US-based company that provides instruments, software, services, and consumables for laboratories, revealed a new agreement with Incyte, a US-based pharmaceutical company. This partnership is designed to leverage Agilent’s specialized knowledge and established success in developing companion diagnostics (CDx) to bolster the development and commercialization of Incyte’s extensive hematology and oncology product line. Through this joint effort, Agilent gains the opportunity to broaden its CDx portfolio by incorporating novel biomarkers, concurrently, Incyte benefits from Agilent’s proficiency in assay development, securing regulatory approvals, and commercialization strategies, which will aid in supporting clinical trials and achieving CDx registration across both the U.S. and Europe.

Who Are The Firms Contributing To The Companion Diagnostics Market Ecosystem?

Major companies operating in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, Ventana Medical Systems

Access The Complete Companion Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Which Region Contributes The Most To The Companion Diagnostics Market?

North America was the largest region in the companion diagnostics market in 2025. The regions covered in the companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Companion Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=7038&type=smp

Browse Through More Reports Similar to the Global Companion Diagnostics Market 2026, By The Business Research Company

Contact Lenses Market Report 2026

https://www.thebusinessresearchcompany.com/report/contact-lenses-global-market-report

Bionic Contact Lenses Market Report 2026

https://www.thebusinessresearchcompany.com/report/bionic-contact-lenses-global-market-report

Smart Contact Lenses Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-contact-lenses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795